Pharma and Biotech Daily: Key Updates in Drug Development and Regulatory Approvals

Pharma and BioTech Daily

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The European Medicines Agency approved a kidney disease-related label expansion for Novo Nordisk's Ozempic, a GLP-1 drug, after a study showed a reduced risk of death by 20%. Keros suspended two arms of a hypertension study due to safety concerns, causing their stock to plummet. Pfizer's Ibrance showed improved survival in a new breast cancer indication, positioning it as a competitor to Novartis.Executives from Pfizer and Eli Lilly expressed optimism about collaborating with the incoming administration after dining with Trump. In other news, former Cytodyn officials were found guilty of securities fraud, Candel stock soared on promising phase III prostate cancer data, and several companies announced staff layoffs. Pharma M&A spending has been low this year, with only one deal exceeding $5 billion. These developments in the pharmaceutical industry highlight the importance of safety concerns and regulatory approvals in drug development. Stay tuned for more updates on the latest news in Pharma and Biotech.